The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulent M.tb in a ‘challenge’ experiment following vacci...
Príomhchruthaitheoirí: | Tanner, R, Hoogkamer, E, Bitencourt, J, White, A, Boot, C, Sombroek, CC, Harris, SA, O'Shea, MK, Wright, D, Wittenberg, R, Sarfas, C, Satti, I, Verreck, FAW, Sharpe, SA, Fletcher, HA, McShane, H |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
F1000Research
2021
|
Míreanna comhchosúla
Míreanna comhchosúla
-
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
de réir: Tanner, R, et al.
Foilsithe / Cruthaithe: (2021) -
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
de réir: Rachel Tanner, et al.
Foilsithe / Cruthaithe: (2021-01-01) -
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
de réir: Pepponi, I, et al.
Foilsithe / Cruthaithe: (2017) -
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
de réir: Brennan, M, et al.
Foilsithe / Cruthaithe: (2017) -
Tools for assessing the protective efficacy of TB vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection
de réir: Tanner, R, et al.
Foilsithe / Cruthaithe: (2020)